What endocrine effects are associated with lithium therapy?

Endocrine Effects of Lithium

Lithium therapy requires periodic thyroid evaluation and monitoring for multiple endocrine complications including hypothyroidism, goiter, hyperparathyroidism with hypercalcemia, and nephrogenic diabetes insipidus. 1, 2

Thyroid Effects

Lithium inhibits thyroid hormone secretion and interferes with the iodine symporter, making thyroid dysfunction the most common endocrine complication 3, 4:

• Hypothyroidism occurs in 8-20% of patients, with higher risk in women and those with pre-existing thyroid autoimmunity 3, 4
• Goiter develops early in treatment, with prevalence 4 times higher than the general population 3, 4
• Euthyroid goiter and/or hypothyroidism (including myxedema) accompanied by lower T3 and T4 levels are documented adverse reactions 2
• Hyperthyroidism is paradoxically reported in approximately 5% of cases, though the causal relationship remains unproven 3

The FDA label explicitly states that all patients receiving lithium therapy require periodic thyroid evaluation because lithium may induce goiter and hypothyroidism 1, 2.

Parathyroid Effects

Lithium stimulates parathyroid cell proliferation by activating the Wnt pathway 3, 4:

• Hypercalcemia and elevated PTH occur in approximately 30% of patients 3
• Primary hyperparathyroidism risk is 4-6 times higher than the general population 4
• Unique phenotype: Unlike typical hyperparathyroidism, lithium-induced cases often present with low or normal 24-hour urine calcium (mimicking familial hypocalciuric hypercalcemia) due to lithium's action on the calcium-sensing receptor (CaSR) 3, 4
• Parathyroid hyperplasia is more common than adenoma, requiring cautious surgical approach 4

Renal/Metabolic Effects

Nephrogenic diabetes insipidus is a major endocrine complication 2:

• Chronic lithium therapy may cause diminished renal concentrating ability, presenting as polyuria and polydipsia 2
• This condition is not always reversible after lithium discontinuation, especially in patients with chronic kidney disease from interstitial tubule nephritis 4
• Nephrogenic diabetes insipidus increases risk of dehydration, hypernatremia, and hypercalcemia 3
• The FDA label warns that patients should be carefully managed to avoid dehydration with resulting lithium retention and toxicity 2

Monitoring Recommendations

Based on the FDA label and clinical guidelines 1, 2, 3, 4:

Required baseline and periodic monitoring:

• TSH - to detect hypothyroidism
• Serum calcium - to detect hyperparathyroidism
• Serum sodium - to detect hypernatremia from diabetes insipidus
• Serum creatinine - to assess renal function
• Serum lithium levels - to prevent toxicity

Clinical assessment should include:

• Evaluation for goiter (thyroid enlargement)
• Assessment of urine output (polyuria suggests diabetes insipidus)
• Symptoms of hypercalcemia (fatigue, cognitive changes)

Critical Pitfalls

1. Detection bias: Recent data shows substantially higher rates of blood testing in lithium users versus controls, potentially overestimating adverse event rates 5. However, severe outcomes remain rare (e.g., chronic kidney disease in only 0.6% of patients) 5.

2. Discontinuation risk: The risk of lithium discontinuation for endocrine side effects must be weighed against psychiatric relapse risk and requires discussion with the treating psychiatrist 4.

3. Parathyroid surgery: When hyperparathyroidism requires surgery, be aware that hyperplasia is more common than adenoma, and hypercalcemia may persist post-operatively 6.

4. Irreversible effects: Nephrogenic diabetes insipidus may not resolve after stopping lithium, particularly with prolonged exposure 4.